HUISARTS EN WETENSCHAP Content Navigatie Servicelinks Zoeken
Blader huidige nummer

Blader huidige nummer

homeNHG: standaard

NHG: standaard

NHG-Standaard Preventie en vroegdiagnostiek van cervixcarcinoom.

Tweede herziening

Huisarts en Wetenschap, jaargang 2009, nummer 4:182-191

Huisarts en Wetenschap jaargang 52, nummer 4 (2008) p. 182-91 Zie voor de tekst van NHG-Standaard de NHG-website: www.nhg.org.

  1. 1. Bij verwijzingen naar NHG-producten: zie www.nhg.org.
  2. 2. Anonymus. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006;119:1108-24.
  3. 3. Appleby P, Beral V, De Berrington GA, Colin D, Franceschi S, Goodhill A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007;70:1609-21.
  4. 4. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsh P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-93.
  5. 5. Arbyn M, Raifu AO, Autier P, Ferlay J. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007;18:1708-15.
  6. 6. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008;111:167-77.
  7. 7. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-8.
  8. 8. Bailey JV, Kavanagh J, Owen C. Lesbians and cervical screening. Br J Gen Pract 2000;50:481-2.
  9. 9. Bais AG, Van Kemenade FJ, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F, et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer 2007;120:1505-10.
  10. 10. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Viro 2005;32 Suppl l:S16-S24.
  11. 11. Bekkers RL, Meijer CJ, Massuger LF, Snijders PJ, Melchers WJ. Effects of HPV detection in population-based screening programmes for cervical cancer; a Dutch moment. Gynecol Oncol 2006;100:451-3.
  12. 12. Berkers LM, Van Ballegooijen M, Van Kemenade FJ, Rebolj M, Essink-Bot ML, Helmerhorst TJ, et al. Herziening bevolkingsonderzoek op baarmoederhalskanker 1996: hogere dekkingsgraad, minder herhalingsuitstrijkjes en minder opportunistische screening. Ned Tijdschr Geneeskd 2007;151:1288-94.
  13. 13. Bleeker MC, Berkhof J, Hogewoning CJ, Voorhorst FJ, Van den Brule AJ, Starink TM, et al. HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions. Br J Cancer 2005;92:1388-92.
  14. 14. Bleeker MCG, Snijders PJF, Voorhorst FJ, Meijer CJLM. Vlakke penisafwijkingen in de seksuele overdracht van Humaan papillomavirus. Ned Tijdschr Geneeskd 2008;152:993-8.
  15. 15. Boon ME. De Cytobrush-methode. Huisarts Wet 1985;28:322-4.
  16. 16. Boon ME, De Graaff Guilloud-Gentenaar JC. De spatel en het oog. Med Contact 1986;41:477-8.
  17. 17. Boon ME, Suurmeijer AJH. The Pap Smear. Leiden: Coulomb Press Leyden, 1993.
  18. 18. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human
  19. 19. papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
  20. 20. Brisson M, Van de Velde N, De Wals P, Boily MC. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ 2007;77:464-8.
  21. 21. Buis P, Van den Heuvel L, Balfoort A, Chorus R, Van Diest P. Mindere kwaliteit van cervixuitstrijkjes afgenomen door doktersassistentes in vergelijking met huisartsen. Huisarts Wet 2006;49:24-7.
  22. 22. Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer 2005;113:1005-9.
  23. 23. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94-101.
  24. 24. Bulkmans NW, Bulk S, Ottevanger MS, Rozendaal L, Hellenberg SM, Van Kemenade FJ, et al. Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate. J Clin Pathol 2006;59:1218-20.
  25. 25. Bulkmans NWJ, Berkhof J, Rozendaal L, Van Kemenade FJ, Boeke AJP, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370:1764-72.
  26. 26. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996;174:927-36.
  27. 27. Centraal Medisch Tuchtcollege. Uitspraak Centraal Medisch Tuchtcollege d.d. 27 oktober 1994. Verontrustende uitslag uitstrijkje niet doorgegeven: maatregel van waarschuwing bevestigd. Medisch Contact 1995;50:457-8.
  28. 28. Coste J, Cochand-Priollet B, De Cremoux P, Le Gales C, Cartier I, Molinie V, et al. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. BMJ 2003;326:733.
  29. 29. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362:1871-6.
  30. 30. D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56.
  31. 31. Davey E, Barratt A, Irwig L, Chan SF, Macaskill P, Mannes P, et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 2006;367:122-32.
  32. 32. De Kok IMCM, Habbema JDF, Mourits MJE, Coebergh JWW, Van Leeuwen FE. Onvoldoende gronden voor opname van vaccinatie tegen Humaan papillomavirus in het Rijksvaccinatieprogramma. Ned Tijdschr Geneeskd 2008;152:2001-3.
  33. 33. De Nooijer DP, De Waart FG, Van Leeuwen AW, Spijker WW. Opkomst bij bevolkingsonderzoek naar baarmoederhalskanker hoger na uitnodiging door de huisarts, in het bijzonder voor groepen met doorgaans lage participatiegraad. Ned Tijdschr Geneeskd 2005;149:2339-43.
  34. 34. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al.; Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
  35. 35. Fokke HE, Salvatore CM, Schipper ME, Bleker OP. A randomized trial of three methods of obtaining Papanicolaou smears. Eur J Obstet Gynecol Reprod Biol 1993;48:103-6.
  36. 36. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
  37. 37. Gezondheidsraad. Vaccinatie tegen baarmoederhalskanker. Den Haag: Gezondheidsraad, 2008.
  38. 38. Giard RWM, Hermans J, Doornewaard H. Landelijke resultaten van cervixcytologische diagnostiek in 1992; de screening kan doelmatiger. Ned Tijdschr Geneeskd 1994;138:1325-30.
  39. 39. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
  40. 40. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
  41. 41. Hermens RP, Tacken MA, Hulscher ME, Braspenning JC, Grol RP. Attendance to cervical cancer screening in family practices in The Netherlands. Prev Med 2000;30:35-42.
  42. 42. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC e.a. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-53.
  43. 43. IKCnet. Nederlandse kankerregistratie. Incidentiecijfers (2005). www.IKCnet.nl. Geraadpleegd oktober 2008.
  44. 44. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693-1702.
  45. 45. Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 2004;8:1-78.
  46. 46. Klinkhamer PJ, Meerding WJ, Rosier PF, Hanselaar AG. Liquid-based cervical cytology. Cancer 2003;99:263-71.
  47. 47. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
  48. 48. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-75.
  49. 49. Kreuger FA, Van Oers HA, Nijs HG. Cervical cancer screening: spatial associations of outcome and risk factors in Rotterdam. Public Health 1999;113:111-5.
  50. 50. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579-88.
  51. 51. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-97.
  52. 52. Nederlandse Vereniging voor Pathologie. Praktijkrichtlijn versie 2.1. Voor kwaliteitsborging van cytopathologisch onderzoek van de baarmoederhals. Eindhoven/Amsterdam: NVVP, 2006.
  53. 53. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25:4931-9.
  54. 54. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70.
  55. 55. Pagliusi SR, Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23:569-78.
  56. 56. Palefsky JM, Holly EA. Immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr 2003:41-6.
  57. 57. Palm BThM, Kant AC. Bevolkingsonderzoek baarmoederhalskanker. De invloed van de huisarts op deelname en follow-up. Nijmegen: Katholieke Universiteit Nijmegen, 1994.
  58. 58. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24 Suppl 3:S11-S25.
  59. 59. Rebolj M, Van Ballegooijen M, Berkers LM, Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2007;120:806-12.
  60. 60. Sawaya GF, Smith-McCune K. HPV vaccination--more answers, more questions. N Engl J Med 2007;356:1991-3.
  61. 61. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
  62. 62. Schmeink CE, Lenselink CH, Bekkers RLM. Pilgebruik en een verhoogde kans op cervixcarcinoom. Ned Tijdschr Geneeskd 2008;152:1717-8.
  63. 63. Shapley M, Jordan J, Croft PR. A systematic review of postcoital bleeding and risk of cervical cancer. Br J Gen Pract 2006;56:453-60.
  64. 64. Siebers AG, Klinkhamer PJ, Arbyn M, Raifu AO, Massuger LF, Bulten J. Cytologic detection of cervical abnormalities using liquid-based compared with conventional cytology: a randomized controlled trial. Obstet Gynecol 2008;112:1327-1334.
  65. 65. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32.
  66. 66. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006;208:152-64.
  67. 67. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 2006;24 Suppl 3:S106-S13.
  68. 68. Tacken M. Opkomst baarmoederhalskankerscreening: huisartsen organiseren het goed. Huisarts Wet 2002;45:109.
  69. 69. Van Ballegooijen M, Van den Akker-Van Marle E, Patnick J, Lynge E, Arbyn M, Anttila A, et al. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000;36:2177-88.
  70. 70. Van Kemenade FJ, Wiersma T, Helmerhorst TJ. Nieuwe versie van de pathologiepraktijkrichtlijn voor cervixcytologisch onderzoek: criteria voor adequaatheid aangescherpt; gebruik van nieuwe technieken verruimd. Ned Tijdschr Geneeskd 2007;151:1283-6.
  71. 71. Van Veen WA. Huisarts en cervixscreening: meer te bereiken met minder uitstrijken. Huisarts Wet 1994;37:226-9.
  72. 72. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
  73. 73. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-66.
  74. 74. Vinkesteijn ASM, Siemens FC, Boon ME, Kuypers JC, Kok LP. Geen groot verschil tussen bevolkingsonderzoek op cervixcarcinoom bij het huidige screeningsinterval van 5 en het vorige van 3 jaar. Ned Tijdschr Geneeskd 2004;148;36:1781-5.
  75. 75. Vooijs GP. De advisering bij afwijkende bevindingen van cytologisch onderzoek van de cervix uteri. Ned Tijdschr Geneeskd 1987;131:1662-3.
  76. 76. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, et al. Condom use and the risk of genital human papilloma virus infection in young women. N Engl J Med 2006;345:2645-54.
  77. 77. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-6.
  78. 78. Woodman CB, Collins S, Rollason TP, Winter H, Bailey A, Yates M, et al. Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet 2003;36:40-3.
  79. 79. World Health Organization, Department of Immunization VeB. Human papillomavirus and HPV vaccines. Technical information for policy-makers and health professionals. Geneve: WHO, 2007.
  80. 80. Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst FJ, Van der Linden HC, Runsink AP, et al. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 2001;85:398-404.
Reacties

lees alle reacties (totaal 0) »

Dit artikel:

Interactief

  • Reageer
  • Lees reacties
  • Stuur door
  • Bewaar
  • Print
  • Mail mij de reacties
  • Voeg artikel toe aan:

Alles over

Zie ook

Zoeken

Zoek binnen: Uitgebreid zoeken

Inloggen
Wachtwoord vergeten?

Abonneren

Meest gelezen

Meer artikelen »
 

Medisch nieuws

Meer Medisch nieuws »
 

Nederlands Huisartsen Genootschap

 

Navigatie

Service

nederlands huisartsen genootschap Bohn Stafleu van Loghum

Copyright © 2012 Bohn Stafleu van Loghum. All rights reserved.